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Abstract
Background: To determine the characteristics of clinical care offered to type 1 diabetic patients across the four
distinct regions of Brazil, with geographic and contrasting socioeconomic differences. Glycemic control, prevalence
of cardiovascular risk factors, screening for chronic complications and the frequency that the recommended
treatment goals were met using the American Diabetes Association guidelines were evaluated.
Methods: This was a cross-sectional, multicenter study conducted from December 2008 to December 2010 in 28
secondary and tertiary care public clinics in 20 Brazilian cities in north/northeast, mid-west, southeast and south
regions. The data were obtained from 3,591 patients (56.0% females and 57.1% Caucasians) aged 21.2 ± 11.7 years
with a disease duration of 9.6 ± 8.1 years (<1 to 50 years).
(Continued on next page)
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Results: Overall, 18.4% patients had HbA1c levels <7.0%, and 47.5% patients had HbA1c levels ≥ 9%. HbA1c levels
were associated with lower economic status, female gender, age and the daily frequency of self-blood glucose
monitoring (SBGM) but not with insulin regimen and geographic region. Hypertension was more frequent in the
mid-west (32%) and north/northeast (25%) than in the southeast (19%) and south (17%) regions (p<0.001). More
patients from the southeast region achieved LDL cholesterol goals and were treated with statins (p<0.001). Fewer
patients from the north/northeast and mid-west regions were screened for retinopathy and nephropathy,
compared with patients from the south and southeast. Patients from the south/southeast regions had more
intensive insulin regimens than patients from the north/northeast and mid-west regions (p<0.001). The most
common insulin therapy combination was intermediate-acting with regular human insulin, mainly in the north/
northeast region (p<0.001). The combination of insulin glargine with lispro and glulisine was more frequently used
in the mid-west region (p<0.001). Patients from the north/northeast region were younger, non-Caucasian, from
lower economic status, used less continuous subcutaneous insulin infusion, performed less SBGM and were less
overweight/obese (p<0.001).
Conclusions: A majority of patients, mainly in the north/northeast and mid-west regions, did not meet metabolic
control goals and were not screened for diabetes-related chronic complications. These results should guide
governmental health policy decisions, specific to each geographic region, to improve diabetes care and decrease
the negative impact diabetes has on the public health system.
Keywords: Type 1 diabetes, Glycemic control, Cardiovascular risk factors, Chronic complications, Economic status
Background
Type 1 diabetes mellitus (T1D) is a chronic auto-
immune disease and both genetic and environmental
factors have an important role in its onset. However,
despite a large amount of research that has been con-
ducted in recent decades, the causal factors of this dis-
ease are still unknown [1]. According to the World
Health Organization (WHO), the incidence of T1D is
increasing worldwide [2]. This fact has been observed
in developed [3] and developing countries, including
Brazil [4]. T1D carries a great risk of morbidity and
mortality due to the microvascular and macrovascular
complications that can lead to a lower quality of life
and life expectancy [5]. Currently, these complications
can be postponed by achieving adequate glycemic con-
trol, as demonstrated by the Diabetes Control and
Complications Trial, the Epidemiology of Diabetes
Interventions and Complications Trial and the long-
term follow-up study of the Diabetes Control and
Complications Trial [6,7]. However, many barriers to
achieve adequate glycemic control have been observed
in observational studies, including lack of family sup-
port, fear of hypoglycemia, difficulties in the day-to-
day management of T1D (mainly frequent self-blood
glucose monitoring (SBGM) for insulin dose adjust-
ments), diet, exercise and economic status [8]. Consid-
ering the complexity and cost of following the
recommended guidelines for clinical management of
T1D, economic status represents an important issue in
developing countries [9].
Brazil is the fifth largest country in the world. It has a
tropical climate and comprises 20.8% of American
territory and 47.7% of South American territory and an
estimated population of 191.8 million people. This
results in a demographic density of 22.5 inhabitants/km2
according to the last population census conducted in
2009 by the Brazilian Institute of Geography and Statis-
tics (IBGE) [9]. The self-reported ethnicity is mainly
composed of Caucasians (54%), followed by Mullatos
(44.25%), Afro-Brazilians (6.9%) and Natives (less than
1%). The annual per capita income in 2011 was esti-
mated to be US $12,144 with an uneven distribution
across the geographic regions of the country [10]. Cur-
rently, it is estimated that up to 9.7% of the Brazilian
population is illiterate, although there is great variation,
ranging from 4.26 to 12.21% across the different geo-
graphic regions [9]. Considering the above-mentioned
data, as well as the fact that few national data about the
clinical care of T1D across the geographic regions exist
thus far, the Brazilian Type 1 Diabetes Study Group
(BrazDiab1SG) was organized in 2008. The BrazDiab1SG
is a survey that analyzes the demographic, clinical and
socioeconomic data of T1D patients who have attended
public clinics across Brazil.
The present study aimed to determine the character-
istics of clinical care offered to patients with T1D in
Brazil, including the degree of glycemic control, pres-
ence of cardiovascular (CV) risk factors and frequency
of screening for chronic T1D-related complications
using the American Diabetes Association’s (ADA)
guidelines. In addition, the present study aimed to
evaluate health care practices, disease management and
the frequency that the recommended treatment goals
were met.
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Methods
This study was an observational, cross-sectional, multi-
center study conducted between December 2008 and
December 2010 in 28 secondary and tertiary care public
clinics located in 20 cities in four Brazilian geographic
regions (north/northeast, mid-west, southeast and
south). Detailed methods have been described elsewhere
[11]. Briefly, all patients received health care from the
National Brazilian Health Care System (NBHCS). To be
eligible, the participating centers had to have a diabetes
clinic with at least one endocrinologist. Each clinic pro-
vided data from at least 50 consecutive outpatients with
an initial diagnosis of T1D who regularly attended the
clinic. The inclusion criteria included a diagnosis of T1D
by a physician based on typical clinical presentation, in-
cluding a variable degree of weight loss, polyuria, poly-
dipsia and polyphagia, in addition to the need to use
insulin continuously since the diagnosis without inter-
ruption. All patients were diagnosed between 1960 and
2010.
Demographic data, educational data and economic sta-
tus were also obtained. Patients with diabetes for less
than five years in duration, were not included in the ana-
lysis of diabetic complications (n=1,160; 32.3%). As listed
in Appendix 1, each local center’s ethics committee
approved the study. The Brazilian Diabetes Society coor-
dinated the study by monitoring and reviewing all study-
related documents and approving all amendments and
publications. The standardized form used for data col-
lection was reviewed by leading diabetologists in Brazil
before the final approval.
The following variables were assessed through an
interview during a clinical visit: current age, age at diag-
nosis, duration of diabetes (y), height (m), weight (kg),
blood pressure (systolic and diastolic in mmHg), dia-
betes treatment modalities, comorbidities, frequency of
SBGM and smoking status. HbA1c, fasting plasma glu-
cose (FPG), total cholesterol, LDL cholesterol, HDL
cholesterol and triglycerides levels recorded during the
last visit to the clinic were obtained from the medical
records. In addition, it was also documented whether
retinopathy screening by fundoscopy, nephropathy
screening by microalbuminuria or a foot examination
had been conducted within one year of the study assess-
ment in patients who had been diagnosed with diabetes
for longer than five years [12].
The following ADA goals for good metabolic and clin-
ical control [12] were adopted by the BrazDiab1SG:
HbA1c < 7.5% for T1D patients 13 to 19 years of
age; HbA1c <8% for T1D patients 6 to 12 years of age;
HbA1c > 7.5% and < 8.5 % for T1D patients aged less
than 6 years old; HbA1c < 7% for adult T1D patients;
systolic blood pressure (sBP) < 130 mmHg; diastolic
blood pressure (dBP) < 80 mmHg; body mass index
(BMI) < 25 kg/m2; FPG < 130 mg/dl (7.2 mmol/l); total
cholesterol < 200 mg/dl (5.2 mmol/l); HDL cholesterol >
40 mg/dl for men (1.1 mmol/l) and > 50 mg/dl (1.3
mmol/l) for women; LDL cholesterol < 100 mg/dl (2.6
mmol/l); non-HDL cholesterol < 130 mg/dl (3.30 mmol/
l); and triglycerides < 150 mg/dl/l (1.7 mmol/l).
In adults, hypertension was defined as a measurement
of sBP ≥ 140 mmHg and/or dBP ≥ 90 mmHg during the
last visit [12], the use of an anti-hypertensive drug or
self-reported identification. In children and adolescents,
hypertension was defined as a sBP or dBP ≥ the 95th
percentile for age, sex and height [13]. In adults, over-
weight was defined as having a BMI ≥ 25 kg/m2, and
obesity was defined as having a BMI ≥ 30 kg/m2 [14]. In
children and adolescents, overweight was defined as hav-
ing a BMI ≥ the 85th percentile for age and gender, and
obesity was defined as having a BMI ≥ the 95th percent-
ile for age and gender [14].
HbA1c values and the methods used for its measure-
ment were collected from medical charts. In 3,367
patients (93.7%), HbA1c levels were measured using
methods certified by the National Glycohemoglobin
Standardization Program (NGSP), including high-
performance liquid chromatography in 1,766 patients
(51.3%) and turbidimetry in 1,601 patients (46.6%).
HbA1c levels determined using methods not certified by
the NGSP, missing data and HbA1c levels determined
more than one year before the study assessment were
excluded from the analysis of glycemic control (n=494;
13.8%). FPG, triglycerides, HDL and total cholesterol
were measured using enzymatic techniques. LDL levels
were calculated using Friedewald’s equation [15]. BMI
(kg/m2) was determined by dividing the weight (kg) by
the square of the height (m). A current smoking habit
was defined as a patient smoking more than one
cigarette per day at the time of the interview. The classi-
fication of patients regarding age was as follows: patients
<13 years old were considered children; patients ≥13
years were deemed as adolescents; and patients >18
years were considered to be adults [12]. Written
informed consent for the study was obtained from all the
patients or from the patients’ parents, when necessary.
Statistical analysis
A detailed description of the study sample calculation
has been previously described [11]. Briefly, the study
sample aimed to represent the distribution of T1D cases
across the various geographic regions of Brazil. The pro-
portion of cases in each region was estimated using the
overall population distribution reported in the Popula-
tion Census conducted in 2000 by the IBGE to be 38.8,
31.7, 23.0 and 6.6% in the southeast, north/northeast,
south and mid-west regions, respectively [16]. These
numbers were combined with national estimates of the
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prevalence of diabetes derived from a survey performed
in 1988 to determine the minimum number of patients
to be studied in each region [17]. Concerning the re-
cruitment, each region of the country enrolled > 95% of
its estimated number of T1D patients. Economic status
was defined according to the Brazilian Economic Classi-
fication Criteria [18]. This classification also takes into
account education level, which was categorized as
illiterate/incomplete primary education, complete pri-
mary education/incomplete middle school education,
complete middle school education/incomplete high
school education, complete high school education /some
college education or complete college education. For this
analysis, the following classes of economic status were
considered: high, middle, low and very low income
classes [18].
The data are presented as the means (± SD) for con-
tinuous variables and as counts (relative frequencies) for
discrete variables. Comparisons between genders were
performed using independent two-sided t-tests or
ANOVA for continuous variables and two-sided z-tests
for discrete variables with a normal approximation to the
binomial distribution. Due to the number of variables
tested sequentially, when ANOVAs were used, p-values
were adjusted using the Sidák correction procedure to
control for type I errors and when z-tests were used,
p values < 0.005 were considered significant. For the
other analyses, a two-sided p-value less than 0.05 was
considered significant.
Pearson’s correlation coefficient was calculated when
appropriate. Variables that were not normally distributed
were log transformed. Stepwise multiple regression was
performed with HbA1c levels as dependent variable and
as independent variables, we analyzed the data with the
Person correlation coefficient of <0.1. A multiple logistic
regression (Forward-Wald) was performed with hyper-
tension (yes/no) as the dependent variable. The follow-
ing independent variables were included: ethnicity
(Caucasian or non-Caucasian based on medical charts or
self-reported), age, BMI, geographic region, gender, urine
albumin concentration and economic status. For this
analysis, the Nagelkerke R-squared value was also calcu-
lated. All of the analyses were performed using SPSS ver-
sion 16.0 (Statistical Package of Social Sciences, Chicago,
Illinois). Odds ratios with 95% confidence intervals (CI)
were expressed when appropriate.
Results
Demographics, socioeconomic status, level of care and
treatment modalities
The distribution of the study population across the geo-
graphic regions of the country and the clinical and demo-
graphic data are shown in Table 1. The majority of the
patients were diagnosed before the age of 15 (n=2,574;
71.7%). The durations of diabetes in the patients were as
follows: <1 to 5 y, n=1,160 (32.3%); 5 to 10 y, n=966
(26.9%); 10 to 15 y, n=642 (17.9%); 15 to 20 y, n=404
(11.3%); and ≥20 y, n=419 (11.7%). Overall, 995 (27.7%)
patients were treated at the secondary care level, and
2,596 (72.3%) patients were treated at the tertiary care
level. More patients from the north/northeast and mid-
west regions attended secondary care centers compared to
patients from the southeast and south regions (60.9, 73.1,
7.1 and 5.5% for north/northeast, mid-west, southeast and
south, respectively; p<0.001). The average follow-up time
in the participating centers was 6.1 ± 5.8 y.
There were differences in age, age at diagnosis, ethni-
city, economic status, care level and duration of diabetes
across the regions of the country. Patients from the
north/northeast region were younger, non-Caucasian
and from very low or low economic status, compared to
patients from the other regions of the country (Table 1).
Diabetes treatment was also different across the
regions. Fewer patients from the north/northeast region
used continuous subcutaneous insulin infusion (CSII)
and performed SBGM daily (p<0.05). Overall, 559
patients (15.6%) used only intermediate-acting human
insulin (NPH) or long-acting insulin (glargine or dete-
mir); there was a significant difference in the use of ei-
ther intermediate-acting human insulin or long-acting-
insulin (glargine or detemir) across the geographic
regions (p<0.001). The most frequently found modality
of insulin monotherapy was the use of intermediate-
acting human insulin (NPH) (Table 1). More patients
from the south and mid-west regions used only insulin
glargine or detemir compared to patients from the
southeast or northeast/north regions (p<0.001) (Table 1).
More patients from the south/southeast region were
treated with intermediate-acting/long-acting plus short-
acting insulin and used three or more daily injections of
short-acting insulin, compared to patients from the
north/northeast and mid-west regions (Table 1).
Insulin therapy combinations were used by 2,989
(83.2%) patients, and there were large differences among
the types of combinations used across the country
(p<0.001). The most frequent combination of insulin
therapy for all the geographic regions was intermediate-
acting human insulin (NPH) with human regular insulin.
This type of combination was more frequent in the
north/northeast region compared to the other regions
(p<0.001). The combinations of insulin glargine with in-
sulin lispro and insulin glargine with insulin glulisine
were more frequently used by patients from the mid-
west region (p<0.001). These data are shown in Table 2.
Glycemic control
Clinical and laboratory data, as well as the proportions
of patients who underwent clinical and biochemical
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evaluations showing that they achieved the ADA criteria
for good metabolic control in the various geographic
regions are shown in Table 3. Overall, more patients
from the north/northeast (n=358; 32.2%) and mid-west
(n=38; 16.2%) regions than patients from the southeast
(n=83; 5.8%) and south (n=15; 1.8%) regions had their
HbA1c levels excluded due to the following reasons:
missing data; HbA1c levels were determined using
Table 1 Clinical and demographic data of the study population according to geographic region
Variable Southeast South North/ Northeast Mid-west P Value
N(%) 1,424 (39.7) 820 (22.8) 1,113 (31.0) 234 (6.5)
Gender, F (%) 821 (57.7) 461 (56.2) 593 (53.3) 135 (57.7) 0.21
Age, y 21.6 ± 12.4 22.3 ± 12.2 19.9 ± 10.1† 21.2 ± 11.9 <0.001
Age, y (%) 0.19
0–5.9 57 (4) 18 (2.2) 41 (3.7) 14 (6.0)
6–12.9 279 (19.6) 148 (18.0) 239 (21.5) 56 (23.9)
13–18.9 370 (26.0) 225 (27.4) 296 (26.6) 40 (17.1)
≥19.0 719 (50.4) 429 (52.3) 537 (48.2) 124 (53.0)
Age at diagnosis, y (%) <0.001
0–4.9 318 (22.3) 133 (16.2) 169 (15.2) 47 (20.1)
5–9.9 401 (28.2) 227 (27.7) 280 (25.2) 53 (22.6)
10–14.9 370 (26.0) 243 (29.6) 285 (25.6) 43 (18.4)
15-19.9 160 (11.2) 103 (12.6) 186 (16.7) 43 (18.4)
20–29.9 121 (8.5) 82 (10.0) 160 (14.4) 41 (17.5)
≥30 54 (3.8) 32 (3.9) 33 (3.0) 7 (3.0)
Ethnicity, n (%) <0.001
Caucasian 830 (58.9) 716 (87.3) 383 (34.4) 111 (47.4)
Non-Caucasian* 585 (41.1) 104 (12.7) 730 (65.6) 123 (52.6)
Economic status** <0.001
High 98 (7.2) 82 (10.2) 36 (3.4) 24 (10.9)
Medium 361(26.4) 248 (30.9) 101 (9.4) 63 (28.6)
Low 496 (36.3) 311 (38.1) 302 (28.2) 68 (30.9)
Very low 412 (30.1) 161 (20.1) 633 (59.0) 65 (29.5)
Years of Study 9.7 ± 4.5 9.5 ± 3.9 9.9 ± 4.5 10.5 ± 5.2† 0.01
Duration of diabetes, y 10.7 ± 8.8 10.6 ± 8.4 7.6 ± 6.4†† 8.6 ± 7.5†† <0.001
Treatment of diabetes n(%)
Insulin *** <0.001
Intermediate or long acting 157 (11) 49 (6.0) 291 (26.2) 62 (26.5)
CSII**** 23 (1.6) 10 (1.2) 2 (0.2) 4 (1.7)
Intermediate/long plus short acting 1,241 (87.3) 761 (92.8) 819 (73.7) 168 (71.8)
Short acting shots ≥ 3 /day 832 (64.7) 570 (73.0) 408 (48.7) 103 (50.9) <0.001
SBGM, yes (%) 1,331(93.5) 763 (93.0) 853 (76.6) ††† 221 (94.4)
Specialist visits in the prior, y 1,424(99.0) 819 (99.8) 1,097 (98.5) 226 (96.6) 0.3
Level of care n (%)
Secondary 101(7.1) 45 (5.5) 678 (60.9) 171(73.1) <0.001
Tertiary 1,323(92.9) 775(94.5) 435 (39.1)# 63(26.9)#
The data are presented as the means (SD) and n (%); y = years; f = female, SBGM = self-blood glucose monitoring.† p<0.01 vs. each other region; ††P<0.05 vs. each
other region; ††† p<0.001 vs. each other region # P< 0.01 vs. south and southeast regions.
* African-Brazilians, Mulattos, Asians, Native Aborigines.
** Data not available from 130 (3.6%) patients *** Data not available from 4 (0.001%) patients.
****CSII: continuous subcutaneous insulin infusion.
For comparison between continuous variables ANOVA with Sidak correction were used; For comparison between discrete variables two-sided z-tests with
correction was used.
Gomes et al. Diabetology & Metabolic Syndrome 2012, 4:44 Page 5 of 12
http://www.dmsjournal.com/content/4/1/44
methods not certified by the NGSP; or HbA1c levels
were determined more than one year before the study
assessment. The frequencies of HbA1c level determina-
tions per year were also different across the country
(2.8 ± 1.4, 3.0 ± 1.0, 2.0 ± 1.2, and 1.9 ± 1.0/year for
the southeast, south, north/northeast and mid-west,
respectively; p<0.001).
Overall, 570 (18.4%) patients achieved the ADA cri-
teria for good metabolic control, with the majority of
these patients (48.5%) being from the southeast region.
Of the entire study population, 1,472 (47.5%) patients
had HbA1c levels ≥ 9%.
When stepwise multiple regression analysis was ap-
plied with HbA1c level as the dependent variable and
the independent variables being the geographic region of
the country, duration of diabetes, insulin regimen, age,
economic status, daily frequency of SBGM and gender, it
was shown that low/very low economic status, (r=0.10,
r2=0.01, and B=0.22; p < 0.001), daily frequency of
SBGM (r=0.14, r2=0.02, and B=−0.13; p = 0.001), female
gender (r=0.16, r2=0.02, and B=0.40; p < 0.001) and age
(r=0.17, r2=0.03, and B=−0.013; p< 0.001) were asso-
ciated with HbA1c levels. Associations with insulin regi-
men, region of the country and duration of diabetes did
not reach statistical significance.
Cardiovascular risk factors and specific therapy
Clinical and laboratory data, as well as the proportions
of patients who underwent clinical and biochemical eva-
luations showing that they achieved the ADA criteria for
CV risk factors according to the geographic regions are
shown in Table 3.
Overweight and obesity were observed in 820 (22.8%)
and 286 (8.0%) patients, respectively. More patients from
the north/northeast region achieved the healthy target
BMI (p<0.001) than patients from other regions of the
country. A current smoking status was reported by 150
(4.2%) patients and was more frequent among patients
from the South region than among patients from other
regions of the country (p<0.001).
Hypertension was observed in 689 (19.2%) patients,
and the frequency of hypertension was also different
among the regions of the country (32.0, 25.0, 19.0
and 17.0% for the mid-west, north/northeast, south-
east and south, respectively, p<001). Among all of
the patients with hypertension, 333 (48.1%) under-
went treatment. Among the hypertensive patients,
321 (47.1%) and 240 (35.2%) were within the targets
for sBP and dBP, respectively. Overall, 76 (22.9%) of
the patients with hypertension who were using anti-
hypertensive agents were within the targets for both
sBP and dBP.
Five hundred thirty-four patients (14.9%) used anti-
hypertensive agents, and the use of anti-hypertensive
agents was related to the region of the country (44.9,
28.1, 20.4 and 6.6% for the southeast, south, north/
northeast and mid-west, respectively; p<0.001). The
most frequently used anti-hypertensive agents were
angiotensin-converting-enzyme (ACE) inhibitors, which
were used by 335 (57.2%) patients.
Table 2 Types of insulin therapy according to geographic region
Insulin Monotherapy *
Type of insulin monotherapy Southeast South Northeast/North Mid-west
NPH 152 (96.8) 41 (83.7) 275 (94.5) 54 (87.1)
Glargine or Detemir 5 (3.2) 8 (16.3) 16 (5.5) 8 (12.9)
Combined Insulin Therapy**
Type of combination of insulin therapy Southeast South Northeast/North Mid-west
NPH plus Regular 573 (46.2) 357 (46.9) 677 (82.7) 79 (47.0)
NPH plus Lispro 271 (21.8) 194 (25.5) 12 (1.5) 11 (6.5)
NPH plus Aspart 91 (7.3) 38 (5.0) 13 (1.6) 4 (2.4)
NPH plus Glulisine 6 (0.5) 4 (0.5) 7 (0.9) 5 (3)
Glargine plus regular 16 (1.3) 12 (1.6) 10 (1.2) 1 (0.6)
Glargine plus Lispro 158 (12.7) 71 (9.3) 25 (3.1) 48 (28.6)
Glargine plus Aspart 57 (4.6) 67 (8.8) 32 (3.9) 6 (3.6)
Glargine plus Glulisine 2 (0.2) 3 (0.4) 3 (0.4) 13 (7.7)
Detemir plus regular 4 (0.3) - 5 (0.6) -
Detemir plus Lispro 25 (2) 3 (0.4) 9 (1.1) 1 (0.6)
Detemir plus Aspart 37 (3) 12 (1.6) 24 (2.9) -
Detemir plus Glulisine 1 (0.1) - 2 (0.2) -
The data are presented as n (%); * /** p<0.001 for comparisons among the groups.
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Table 3 Clinical and laboratory data and screening for chronic complications in the study population according to
geographic region
Southeast South North/Northeast Mid-west P Value
N(%) 1,424(39.7) 820 (22.8) 1,113(31.0) 234 (6.5)
Glycemic Control
HbA1c
Frequency of Complete Records n (%) 1,356 (95.2) 809 (98.7) 978(87.9) 210 (89.7) <0.001
Mean (SD) 9.1 ± 2.3 9.4 ± 2.1# 9.4 ± 2.6# 9.1 ± 2.6 0.002
Patients at Goal 276 (20.6) 98 (12.2)* 154 (20.4) 42 (21.4) <0.001
FPG
Frequency of Complete Records n (%) 1,251 (87.9) 803 (97.9) 1,016 (91.3) 187 (79.9)
Mean (SD) 187.3 (108.4)# 174.4 (94.4) 185.3 ± 108.2# 179.0 ± 102.60 <0.001
Patients at Goal 332 (26.6) 293 (36.5) 301 (29.6) 53 (28.3) <0.001
Cardiovascular Risk Factors
BMI 1,419 (99.6) 819 (99.9) 1,104 (99.2) 226 (96.6)
Frequency of Complete Records n (%)
Mean (SD) 21.9 ± 4.4 22.2 ±3.3* 20.9 ± 4.2 21.7 ± 4.6 0.01
Patients at Goal 942 (66.4) 547 (66.8) 823 (74.5)* 150 (66.4) 0.009
sBP
Frequency of Complete Records n (%) 1,393 (97.8) 811 (98.9) 1,040 (93.4) 193 (82.5)
Mean (SD) 111.4 ± 16.0 111.7 ± 17.9 109.1 ± 17.4* 115.8 (19.3) <0.001
Patients at Goal 1,159 (83.2) 667 (82.2) 893 (85.9) 148 (76.7) 0.009
dBP
Frequency of Complete Records n (%) 1,392 (97.8) 811 (98.9) 1,032 (92.7) 191 (81.6)
Mean (SD) mmHg 71.4 ± 11.02 71.4 ± 11.7 70.9 ± 12.2 71.8 ± 12.2 0.31
Patients at Goal 890 (63.9) 523 (64.5) 709 (68.7) 137 (71.7)* 0.003
Triglycerides (mg/dl)
Frequency of Complete Records n (%) 1,262 (88.6) 496 (60.5) 853 (76.6) 181 (77.4)
Mean (SD) 87.7 ± 69.1 95.3 ± 72.1 103.5 ± 76.9 91.6 ± 58.1 0.006
Patients at Goal 986 (78.1) 407 (82.1) 589 (69.1)* 145 (80.1) 0.001
HDL (Cholesterol)
Frequency of Complete Records n (%) 1,227 (86.2) 487 (59.4) 838 (75.3) 180 (76.9)
Mean (SD) 53.3 ± 14.8* 53.9 ± 15.2*** 50.1 ± 14.1 52.0 ± 12.1 0.01
Patients at Goal n (%) 984 (80.2)**** 369 (75.8) 604 (72.1) 141 (78.3) 0.004
LDL Cholesterol
Frequency of Complete Records n (%) 1,218 (85.5) 483 (58.9) 821 (73.8) 179 (76.5)
Mean (SD) 96.9 ± 33.1*** 102.6 ± 31.3 102.9 ± 35.7 102.1 ± 28.3 <0.002
Patients at Goal n (%) 730 (59.9)* 241 (49.9) 422 (51.4) 89 (49.7) <0.001
Non-HDL Cholesterol 1,227 (86.2) 487(59.4) 835 (75) 180 (76.9)
Frequency of Complete Records n (%)
Mean (SD) 113.7 ± 39.1 ### 121.6 ± 37.5* 122.0 ± 43.1* 119.5 ± 32.7 0.001
Patients at Goal 924 (75.3)**** 322 (66.1) 529 (63.4) 123 (68.3) <0.001
Smoking Status (y), N (%) 56 (4.1) 60 (7.5) 24 (2.2) 10 (4.5) 0.000
Chronic Complications
Feet examination
Yes, n(%) 1,071 (75.2)* 465 (56.7) 588 (52.8) 128 (54.7) <0.001
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When multivariate logistic analysis was applied, the
odds of having hypertension was associated with age
(1.06; 95%CI of 1.05-1.076; p<0.001), BMI (1.13; 95%CI
of 1.09-1.17; p<0.001), albumin excretion rate (1.002;
95%CI of 1.001-1.003; p<0.001) and male gender (1.35;
95%CI of 1.02-1.80; p<0.001). Caucasian ethnicity was
associated with a lower odds ratio of having hyperten-
sion (0.68; 95% CI of 0.51-0.91; p=0.01). This model
explained 25.3% of the probability for a given patient to
be hypertensive.
Overall, 1,785 (49.7%) patients had some type of dysli-
pidemia. Considering the goals for lipid levels, fewer
patients from the north/northeast region achieved the
target for triglycerides and HDL cholesterol levels than
patients from other regions of the country (p=0.001).
More patients from the southeast region achieved the
target for LDL cholesterol levels than patients from the
other regions (p<0.001).
Statins were used by 284 (7.9%) patients, and 112 of
these (42.1%) were within the target for LDL cholesterol
levels. Overall, 1,065 (43.7%) patients had LDL choles-
terol levels above the target levels and were not receiving
treatment. More patients from the Southeast region
were using statins than patients from the other regions
(49.3, 28.5, 17.6 and 4.6% for patients from the south-
east, south, north/northeast and mid-west, respectively;
p<0.001).
Screening for microvascular complications
Screening for microvascular complications was different
across the regions of the country (Table 3). Overall, 25 to
70% of the patients had not been screened for diabetes-
related complications in the previous year. More patients
from the north/northeast and mid-west regions than
patients from the southeast and south regions had not
been screened for diabetic chronic complications in the
previous year. More patients from the south region had
fundoscopies and urine albumin excretion rate evalua-
tions than patients from the other regions (p<0.001).
Furthermore, up to 25% of the records did not have any
information about screening for diabetes-related compli-
cations (data not shown) in the prior year.
Among the patients that had been screened for
chronic diabetes-related complications, 630 (25.9%) had
been screened for coronary artery disease. More patients
from the southeast region had been screened than
patients from the south, north/northeast and mid-west
regions (45.9, 22.4, 27.3 and 4.4% for the southeast,
south, north/northeast and mid-west, respectively). The
most frequently performed tests in this group were elec-
trocardiography (18.6%) and treadmill stress tests (6.7%).
Discussion
The BrazDiab1SG is a survey that analyzes the demo-
graphic, clinical and socioeconomic data of T1D patients
receiving treatment in secondary and tertiary care public
clinics in Brazil.
In the present study, great variability was found in
the proportion of patients screened for diabetes-related
complications and in the proportion of patients reach-
ing their targets depending on the variables evaluated
and on the geographic region of the country. The
southeast and south regions were quite similar regard-
ing patient’s demographic and economic characteristics
but with an important difference from the patients
from the north/northeast and mid-west. Overall, more
patients from the north/northeast attended secondary
care level centers, tended to be younger, tended to be
non-Caucasian and tended to be from a lower eco-
nomic status.
For most patients, blood pressure levels were within
the goals. However, glycemic control was unsatisfactory
in the majority of the study patients. Being overweight
was an important issue in all regions of the country
and was observed in one-third of the study patients.
Additionally, approximately half of the patients were
not screened for diabetic complications in the previous
year. It is important to mention that all of the patients
were treated by an endocrinologist at secondary and
tertiary care clinics.
The treatment of diabetes in Brazil is guided by the
Brazilian Diabetes Society , whose recommendations are
essentially the same as those of the ADA. Considering
that diabetes treatment in public clinics is financed by
the National Brazilian Health Care System, the present
data showed that factors other than medical recommen-
dations likely interfere with diabetes care in Brazil, espe-
cially social and economic factors. The latter fact may be
Table 3 Clinical and laboratory data and screening for chronic complications in the study population according to
geographic region (Continued)
Fundoscopy y, n(%)
Yes,n (%) 714 (50.1)+ 462 (56.3)* 427 (38.4) 80 (34.2) <0.001
Urine Albumin
Yes, n (%) 661 (46.4)+ 484 (59)* 361 (32.4) 72 (30.8) <0.001
Data are presented as the means (SD) and n (%); y = yes * P<0.001 vs. each other region; *** p<0.002 vs. each other region; **** p<0.01 vs. each other region;
### p<0.005 vs. each other region; + p<0.01 vs. north/northeast and mid–west regions For comparison between continuous variables ANOVA with Sidak
correction were used; For comparison between discrete variables two-sided z-tests with correction was used.
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associated with the low or very low economic status that
was found in up to 87% of the studied patients, mainly
in the north/northeast region of the country. Notably,
economic status in Brazil also takes into account educa-
tional level. In the last Brazilian population census [9],
the north/northeast region presented a higher number
of illiterates (12.2%) than the national average (9.7%) and
the proportion observed in the southeast (4.45%), south
(4.26%), and mid-west (6%). Considering the existing
complexity of T1D management, the above-mentioned
facts may have influenced the lower use of CSII, SBGM
and intermediate-acting/long-acting plus short-acting in-
sulin by the north/northeast region. Although patients
from the north/northeast region had a lower duration of
diabetes, it is important to emphasize that no difference
was observed concerning the number of visits to a spe-
cialist in the prior year among all of the geographic
regions of the country.
The present study found great heterogeneity in the
type of human intermediate-acting/long-acting plus
short-acting insulin used by the patients across the Bra-
zilian geographic regions. Although the most frequent
type of association in all regions was human
intermediate-acting insulin NPH with regular human in-
sulin, the combination of insulin glargine with insulin
lispro or glulisine was more frequently used in the mid-
west region. No clear explanation exists for this trend,
but it may be explained by the local health policy re-
sponsible for the acquaintance of insulin. Although dia-
betes treatment in public clinics is financed by the
National Brazilian Health Care System, it is important to
emphasize that each city’s health bureau acts independ-
ently from the federal government and has its own rules
concerning the choice of what type of insulin they are
going to purchase and furnish to their diabetic
population.
Approximately 13.8% of the HbA1c determinations,
mainly in the north/northeast and mid-west regions,
were excluded due to the following reasons: the methods
used were not certified by the NGSP; existence of miss-
ing data; or the HbA1c level was determined more than
one year before the study assessment. Moreover, among
those patients who had undergone HbA1c measure-
ments in the prior year to the study, the average number
of measurements was also different across the geo-
graphic regions, with a lower number performed in the
north/northeast and mid-west regions. In general,
patients from the southeast and south regions performed
a similar number of HbA1c determination to that pro-
posed by ADA guidelines [12] and the Brazilian Diabetes
Society recommendations [19] but varied widely from
one to ten per year. This range indicates that there is no
agreement in Brazil regarding the number of HbA1c
measurements routinely performed to monitor the
treatment of a patient with T1D. Other factors related to
the physician’s interpretation of the test might explain
these discrepancies.
Although most patients had complex therapeutic regi-
mens and performed SBGM, more than 40% of the
patients had HbA1c levels greater than 9%, thereby in-
dicating poor glycemic control. Although the north/
northeast and south regions had the highest average
HbA1c levels, the lowest proportion of patients reaching
the goal of HbA1c was observed in the south region.
However, it is important to emphasize that in the multi-
variate analysis (after correcting for age, economic status,
gender and daily frequency of SBGM) neither the geo-
graphic region of the country nor the type of insulin regi-
men that was used reached statistical significance. The
latter fact must be analyzed in the context of the high
costs of CSII and long-acting insulin analogues (glargine
and detemir). Although the present study was not
designed to evaluate the cost-effectiveness of both types
of treatment, the data could add new insights for
reforming the guidelines of the National Brazilian Health
Care System concerning the treatment of T1D in Brazil.
Thus far, the majority of the studies that have addressed
this issue have found that both types of treatment are
mainly associated with an improvement in the occur-
rence of severe hypoglycemia but not with improved gly-
cemic control, thereby showing that a gap exists
between the large amounts of money spent with the
treatment of T1D and the final outcomes in terms of
glycemic and CV risk factors control [20-24]. However,
the overall difficulty in achieving glycemic control in
T1D patients through routine care is described in many
observational studies worldwide [17-19,25-28].
Currently, the therapeutic and clinical management
of weight, cholesterol and blood pressure is of great
importance for delaying or preventing diabetes-related
microvascular and macrovascular complications. Al-
though most of the studied patients achieved the sBP,
dBP and HDL cholesterol goals, 30 to 50% did not
reach the goals for triglycerides, LDL cholesterol and
non-HDL cholesterol levels, which was similar to the
data found in other observational studies [7,18,28-30].
Although there is a slight prevalence of patients that
have reached BMI levels resembling Brazilian over-
weight/obesity statistics [31], the present results sug-
gested an additional major health issue in T1D
patients in all geographic regions is overweight or
obese patients, which was similar to results found in
other populations with T1D [7,18,32,33] and in
patients with T2D in Brazil [9].
Although the guidelines recommend aggressive dysli-
pidemia and hypertension treatments in T1D patients,
despite the presence of high BP and LDL cholesterol, up
to 50% of the studied patients were not receiving
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treatment for both clinical conditions during this study.
Similar results have also been described in Sweden [18].
Hypertension was observed in 19.2% of the patients
with a higher proportion in patients from the mid-west
and north/northeast regions than patients from the
southeast and south regions. Until recently, no data
were available concerning hypertension prevalence in
T1D Brazilian patients. Overall, almost half of the
studied patients had some type of dyslipidemia, but
only 7.9% of these patients were using statins for dysli-
pidemia. Of these patients, fewer than 50% were at
LDL cholesterol goals. More patients from the south-
east reached the target for LDL cholesterol than
patients from the other regions, which may have been
due to the more regular use of statins than patients
from the other geographic regions. To the best of our
knowledge, this is the first study to address the above-
mentioned comorbidities in T1D in a multicenter
study in Brazil.
The Pittsburgh Epidemiology of Diabetes Complica-
tions Study used different targets for blood pressure and
LDL cholesterol, and it demonstrated small improve-
ments in hypertension and dyslipidemia control primar-
ily in younger groups of T1D patients over a 10-year
follow-up period [29]. With regard to T1D patients who
were above their goal, one study at academic medical
centers observed a low rate of medication management
[8]. Considering overweight, obesity, hypertension and
dyslipidemia as CV risk factors, it can be concluded that
the young patients in the present study represent a high-
risk group for microvascular and macrovascular compli-
cations of diabetes, as described in other studies
[30,32,33]. Although a high number of current smokers
were noted in the south region in the present study,
there were fewer T1D patients who were current smo-
kers than previously reported in Europe [18] and USA
[34].
Despite that almost one-third of the patients did not
fulfill the criteria for screening for diabetic complica-
tions, up to 60% of the patients conforming to the inclu-
sion criteria had not been screened for diabetic chronic
complications in the previous year. In general, the
screening for diabetic chronic complications was docu-
mented more in the south region, followed by the south-
east region. Fundoscopy and urine albumin testing were
not documented in up 60% of the patients. Notably,
urine albumin evaluation is now regularly performed in
75% of the public hospitals included in the present
study. Moreover, the simplest screening for diabetes-
related complications, which is feet examination, was
not routinely performed in up to 45% of the patients.
The principal strength of the large sample groups in
the present study is that the included cases are represen-
tative of the distribution of T1D in the diverse, young
Brazilian population. Moreover, the epidemiological in-
formation obtained from this study is important for
guiding governmental health policy decisions aimed at
improving diabetes care in Brazil, according to each geo-
graphic region of the country.
Several limitations of the present study must be
addressed. One limitation is the sample characteristics.
Similar to other studies, a clinical definition of T1D
assigned by physicians that was applicable to all patients
was used. However, as autoantibodies and C-peptide
levels were not measured, some patients with other
types of diabetes may have been included. Nevertheless,
it is important to emphasize that 96.5% of the patients
were diagnosed before 30 years of age, which reinforces
the high probability that they most likely had T1D. All
patients were followed in a public center by a specialist
and lived in large cities. Patients who rely on private
clinics, primary care facilities and live in rural areas may
not have been included. However, this group of T1D
patients is considered to be the minority of those receiv-
ing treatment in Brazil. Another limitation is the lack of
standardization for evaluating HbA1c levels. Although
two different methods to determine HbA1c levels were
used across the country, different upper limits of nor-
mality for the same method may be present. This vari-
ation may have also influenced the results of the present
study. However, this variation in methods is still an un-
solved problem in Brazil. Moreover, the consideration of
self-reported hypertension as a criterion of the presence
of the comorbidity may have led to misdiagnosis and
lower reliability in determining the real prevalence of
hypertension.
Conclusions
In conclusion, sufficient screening for diabetic complica-
tions and the target levels for glycemic control, blood
pressure and lipid levels are difficult to achieve in
patients with T1D. Multiple CV risk factors were found
in most patients. The quality of diabetes care must be
substantially improved in Brazil. Among T1D patients
studied in the BrazDiab1SG, large discrepancies were
found in clinical care across the different Brazilian geo-
graphic regions. With few exceptions regarding the dif-
ferences found, this study reinforces the need for a
uniform use of the guideline-recommended therapies, ei-
ther by the Brazilian Diabetes Society or by the ADA, to
improve the quality of diabetes care in Brazil.
Future larger Brazilian prospective studies are war-
ranted to evaluate the cost-effectiveness of more expen-
sive treatment modalities, such as CSII, the use of long-
acting insulin analogues (glargine and detemir), as well
as the costless distribution of strips for SBGM in the
context of the Brazilian healthcare system. The large
amount of money that has been spent with these
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treatment modalities is not showing an expected positive
feed-back in terms of glycemic control and the improve-
ment of cardiovascular risk factors in patients with T1D
in Brazil.
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